Aurinia Pharmaceuticals
Canada
unknown
unknown
Stage
About
Aurinia Pharmaceuticals has developed the first oral therapy for lupus nephritis, a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death.
Explore Aurinia Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.